Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 3/20 | 0.33 |
| ▸ | TACR3 | P29371 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6184557 | 1.00 | GRM5 (0.37) | GRM5BCHEGHSRTACR3CCR2 | |
| SCHEMBL4024991 | 0.84 | L3MBTL1 (0.41) | GRM5TACR3SLC6A4OPRM1OPRK1 | |
| SCHEMBL6172602 | 0.80 | CCR2 (0.36) | TACR3CCR2SLC6A2SLC6A4OPRK1 | |
| SCHEMBL4024987 | 0.78 | GRM5 (0.36) | GRM5SLC6A4OPRK1 | |
| SCHEMBL4019223 | 0.77 | HTR2C (0.41) | GRM5SLC6A4 | |
| SCHEMBL6171159 | 0.73 | SLC6A2 (0.40) | SLC6A2SLC6A4OPRK1 | |
| SCHEMBL6171785 | 0.73 | SLC6A2 (0.40) | SLC6A2SLC6A4OPRK1 | |
| SCHEMBL4028340 | 0.69 | SLC6A2 (0.41) | SLC6A2SLC6A4OPRM1OPRK1 | |
| SCHEMBL4027422 | 0.69 | SLC6A2 (0.41) | SLC6A2SLC6A4OPRM1OPRK1 | |
| SCHEMBL4027425 | 0.69 | SLC6A2 (0.41) | SLC6A2SLC6A4OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1569934-B1 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060052408-A1 | Cyclopropyl compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1569934-A2 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004055010-A2 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052408-A1 | Cyclopropyl compounds as ccr5 antagonists | CCR5, CCR1, CCL5 | GRM5 494/4885BCHE 2417/4885GHSR 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.